Oculis Holding AG increased its at-the-market offering capacity to an aggregate offering price of up to $125,000,000 of ordinary shares under an amended sales agreement with Leerink Partners. The previous agreement covered an aggregate offering price of up to $100,000,000; Oculis had sold $61,323,500 under the agreement as of November 3, 2026.
Sales may be made through or to Leerink Partners as sales agent or principal, subject to placement notices and mutually agreed terms. Oculis may set a minimum sale price or suspend sales with proper notice. Oculis will receive net proceeds and pay commissions of up to 3.0% of gross proceeds. Estimated offering expenses excluding commissions are approximately $1,500,000; separate expense reimbursements are capped at $55,000 for specified expenses and $25,000 per calendar quarter for certain legal costs.
Oculis Holding AG reported a third-quarter 2026 net loss of CHF 18.2 million, versus CHF 16.9 million in 2025; nine-month net loss was CHF 57.1 million versus CHF 75.4 million. The nine-month decrease included CHF 7.3 million in warrant fair-value gains and CHF 3.7 million in foreign-exchange gains, while operating loss rose 13% to CHF 68.9 million and operating cash outflow rose 10% to CHF 54.5 million. Cash, cash equivalents and short-term financial assets totaled CHF 210.3 million at September 30, 2026; management said these resources would fund operations and capital expenditures for at least 12 months under its current operating plan.
Subject to applicable closing conditions, Oculis agreed to acquire Accure Therapeutics’ rights to Privosegtor and ACT-02 for an up-front $3.8 million cash payment and up to 2,050,000 ordinary shares. It also amended the Leerink Partners ATM program, permitting share sales at its sole discretion for an aggregate offering price of up to $125 million; no shares had been sold under the November 3 supplement as of November 3, 2026. Both OCS-01 DIAMOND trials missed the primary endpoint, and Oculis does not plan an FDA filing for DME.
Oculis Holding AG (OCS) announced that director Lionel Carnot’s resignation from the Board of Directors is effective September 30, 2026. Carnot has served on the Board since 2017. Oculis said the departure is a personal decision and is not the result of a disagreement about the company’s operations, policies or practices. After the resignation, the Board will consist of eight members. Geraldine O’Keeffe will chair the Remuneration Committee, with Gregory Perry and Robert Warner as members. Under Swiss law, the vacancy may be filled only at a future annual or special general meeting. Oculis said it will begin identifying a successor and provide updates as appropriate.
Oculis Holding AG agreed to acquire from Accure Therapeutics all development and commercial rights to Privosegtor (ACT-01) and a separate preclinical neurology candidate ACT-02 through an asset purchase agreement with staggered closings.
Total consideration includes an upfront $3.8 million (CHF 3.1 million) cash payment at the first closing and up to 2,050,000 Oculis ordinary shares. The shares comprise upfront stock subject to lockup releases over up to two years and earnout shares vesting upon specified development and regulatory milestones.
Oculis expects to assume existing academic licenses with low single-digit percentage royalties and academic research rights. Completion of the Privosegtor deal will terminate the prior Oculis‑Accure license, eliminating associated milestone and royalty obligations. Closings are expected by February 28, 2027 for Privosegtor and March 31, 2027 for ACT‑02, subject to conditions precedent.
Oculis Holding AG reported unaudited Q2 and first-half 2026 results and described a strategic pivot toward neuro-ophthalmology after its legacy OCS-01 program in diabetic macular edema failed to meet primary endpoints in two Phase 3 DIAMOND trials; the company will not pursue an FDA NDA for this indication, and management concluded there is no impairment to its financial position. The late-stage pipeline now centers on Privosegtor (OCS-05) in the PIONEER registrational program for optic neuritis and non-arteritic anterior ischemic optic neuropathy, and Licaminlimab (OCS-02) in the PREDICT-1 genotype-based registrational trial for dry eye disease, where all sites are activated and over 45% of patients have been randomized with topline data expected around year-end.
For the six months ended June 30, 2026, Oculis recorded a net loss of CHF 38.8 million (CHF 0.65 per share), improved from CHF 58.6 million a year earlier, as operating expenses rose to CHF 45.8 million but were offset by a CHF 4.1 million fair value gain on warrant liabilities and a CHF 1.8 million foreign-exchange gain. Research and development spending was stable at CHF 29.3 million, while general and administrative expenses increased 42% to CHF 16.5 million, driven mainly by higher share-based compensation. Cash, cash equivalents and short-term financial assets totaled CHF 228.3 million (USD 282.3 million) at June 30, 2026, supported by CHF 47.8 million of gross proceeds from an at-the-market share program; management states this provides funding into the second half of 2029.
Oculis Holding furnished an updated corporate presentation outlining late-stage ophthalmic and neuro‑ophthalmic programs and projected funding capacity. The company highlights a strong balance sheet with no debt and a cash runway into 2H 2029, excluding a CHF100 million loan facility.
The presentation centers on two registrational‑stage candidates. Privosegtor, a neuroprotective small molecule for optic neuritis and other optic neuropathies, has FDA Breakthrough Therapy and EMA PRIME designations and a Special Protocol Assessment for the PIONEER‑1 Phase 3 trial. Phase 2 ACUITY data showed clinically meaningful low‑contrast visual acuity gains, anatomical preservation on retinal imaging, reduced neurofilament biomarkers, and no adverse events leading to drug withdrawal or study discontinuation.
Licaminlimab, a topical anti‑TNFα antibody fragment for dry eye disease, is being developed as a precision medicine guided by the TNFR1 genotype. Three Phase 2 trials reported consistent symptom and sign improvements, particularly in genotype‑positive patients, with good tolerability. The ongoing PREDICT‑1 registrational study targets topline results around year‑end 2026. The presentation outlines multiple anticipated milestones through 2027 across both programs.
Oculis Holding AG reported the results of its 2026 Annual General Meeting, where shareholders approved all agenda items and elected Gregory D. Perry to the Board of Directors. The board and executive committee were discharged for 2025 and all incumbent directors were re-elected.
Shareholders acknowledged a standalone statutory loss of CHF 33,670,000 for 2025 and resolved to carry forward an accumulated balance sheet loss of CHF 80,247,000. They approved maximum compensation budgets for non-executive directors and the executive committee, including cash and equity-based awards, and endorsed the 2025 compensation report in an advisory vote.
The meeting approved a capital band of 31,020,888 registered shares, corresponding to a share capital range between CHF 620,417.76 and CHF 930,626.64, and a conditional share capital of 12,677,700 shares for employee and similar plans. Following updated articles, the total number of registered shares increased to 62,041,776, with further board approval to issue 5,750,400 new registered shares into treasury, bringing registered shares up to 67,792,176 and resulting in treasury holdings of 9.15% to support the existing at-the-market offering program and other potential offerings.
Oculis Holding reported an unaudited Q1 2026 net loss of CHF 28.9 million (CHF 0.49 per share), narrowing from CHF 33.2 million a year earlier. Total operating expenses rose to CHF 21.9 million as higher share-based compensation and headcount lifted general and administrative costs, while research and development spending declined slightly as key trials neared completion.
Cash, cash equivalents and short-term financial assets reached CHF 222.0 million as of March 31, 2026, helped by CHF 22.4 million of gross proceeds from an at-the-market share program. Management states this funding supports the business into the second half of 2029. The company’s late-stage pipeline advanced, with Phase 3 DIAMOND trials for OCS‑01 in diabetic macular edema completing last patient visits ahead of a June 2026 topline readout, Licaminlimab’s PREDICT‑1 trial recruiting in dry eye disease, and Privosegtor’s PIONEER‑1 trial in optic neuritis supported by FDA Special Protocol Assessment and PRIME and Breakthrough Therapy designations.
Oculis Holding AG reports that LSP 7 and related parties beneficially own 6,950,294 Ordinary Shares as of March 31, 2026. That stake represents 11.8% of the company based on 59,034,438 Ordinary Shares outstanding. The filing states 1,050,000 shares were purchased by LSP 7 on March 11, 2026, and LSP 7 Management B.V. is the sole director of LSP 7.
Oculis Holding AG is calling shareholders to its 2026 Annual General Meeting on May 13, 2026 in Zug, Switzerland, with an in-person meeting and broadcast.
The agenda covers approval of the 2025 annual and consolidated financial statements, carrying forward a balance sheet loss of CHF 80,247,000, and granting discharge to the board and executive committee. Shareholders will vote on re-electing eight directors, electing a new director, appointing compensation committee members, re-electing PricewaterhouseCoopers as auditor, and electing Blum & Partner AG as independent proxy.
Compensation proposals include up to USD 572,000 fixed and USD 2,150,000 equity-based pay for the board, and up to USD 2,500,000 fixed, USD 1,800,000 variable, and USD 18,000,000 equity-based compensation for the executive committee. The board also seeks to increase the capital band so it can issue up to 31,020,888 additional shares and to expand conditional share capital for employee plans to 12,677,700 shares.
A business update highlights three late-stage programs: OCS-01 eye drops for diabetic macular edema with Phase 3 DIAMOND trial readouts expected in June 2026 and a planned U.S. NDA submission in Q4 2026; Licaminlimab for dry eye disease in the PREDICT-1 registrational trial with topline data expected around late 2026; and Privosegtor, which has Breakthrough Therapy, Orphan Drug and PRIME designations and is entering the PIONEER registrational program for optic neuritis and NAION. Oculis reports oversubscribed equity financings exceeding $200 million in 2025 and is targeting disease areas that together represent estimated market opportunities of over $30 billion.